Posts By: Ryan Confer

Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial

Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline

Presentations to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial